Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018. https://doi.org/10.1038/nrdp.2018.1.
Wajnsztajn D, Nche E, Solomon A. Corneal complications of rheumatoid arthritis. Curr Opin Allergy Clin Immunol. 2022;22(5):304–13.
Sainz de la Maza M, Foster CS, Jabbur NS, Baltatzis S. Ocular characteristics and disease associations in scleritis-associated peripheral keratopathy. Arch Ophthalmol. 2002;120(1):15–9.
Galor A, Thorne JE. Scleritis and peripheral ulcerative keratitis. Rheum Dis Clin North Am. 2007;33(4):835–54, vii.
Tauber J, Sainz de la Maza M, Hoang-Xuan T, Foster CS. An analysis of therapeutic decision making regarding immunosuppressive chemotherapy for peripheral ulcerative keratitis. Cornea. 1990;9(1):66-73.
Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15.
Radu AF, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021. https://doi.org/10.3390/cells10112857.
Angelini J, Talotta R, Roncato R, Fornasier G, Barbiero G, Dal Cin L, et al. Jak-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future. Biomolecules. 2020. https://doi.org/10.3390/biom10071002.
Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Zhou Y, et al. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Rheumatology (Oxford). 2020;59(11):3303–13.
Kremer JM, Emery P, Camp HS, Friedman A, Wang L, Othman AA, et al. A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Arthritis Rheumatol. 2016;68(12):2867–77.
Timlin HM, Hall HN, Foot B, Koay P. Corneal perforation from peripheral ulcerative keratopathy in patients with rheumatoid arthritis: epidemiological findings of the British Ophthalmological Surveillance Unit. Br J Ophthalmol. 2018;102(9):1298–302.
Artifoni M, Rothschild PR, Brézin A, Guillevin L, Puéchal X. Ocular inflammatory diseases associated with rheumatoid arthritis. Nat Rev Rheumatol. 2014;10(2):108–16.
Dana R, Farid M, Gupta PK, Hamrah P, Karpecki P, McCabe CM, et al. Expert consensus on the identification, diagnosis, and treatment of neurotrophic keratopathy. BMC Ophthalmol. 2021;21(1):327.
Bonini S, Rama P, Olzi D, Lambiase A. Neurotrophic keratitis. Eye (Lond). 2003;17(8):989–95.
Font CS, Cortina MS. Neurotrophic keratopathy: update in diagnosis and management. Indian J Ophthalmol. 2025;73(4):483–95.
Cao Y, Zhang W, Wu J, Zhang H, Zhou H. Peripheral Ulcerative Keratitis Associated with Autoimmune Disease: Pathogenesis and Treatment. J Ophthalmol. 2017;2017:7298026.
Wang J, Zhang Q, Shi W, Pang Y, Li S. Peripheral ulcerative keratitis, nodular episcleritis, and pulmonary nodules as the initial signs of rheumatic arthritis: a case report. Front Immunol. 2022;13:1048889.
Mehta K, Gujjar AP, Babu K. Peripheral ulcerative keratitis in a young lady with systemic lupus erythematosus post Rituximab infusion-a case report. Ocul Immunol Inflamm. 2022;30(6):1312–4.
Çakmak A, Akova Y, Yıldırım N. The complete success in refractory Mooren’s ulcer treated with Infliximab. Ocul Immunol Inflamm. 2023;31(4):682–8.
MartÃnez-Abad A, Piñero DP. Pellucid marginal degeneration: detection, discrimination from other corneal ectatic disorders and progression. Contact Lens Anterior Eye. 2019;42(4):341–9.
Gupta Y, Kishore A, Kumari P, Balakrishnan N, Lomi N, Gupta N, et al. Peripheral ulcerative keratitis. Surv Ophthalmol. 2021;66(6):977–98.
Bonnet I, Rousseau A, Duraffour P, Pouchot J, Nguyen CD, Gabison E, et al. Efficacy and safety of rituximab in peripheral ulcerative keratitis associated with rheumatoid arthritis. RMD Open. 2021. https://doi.org/10.1136/rmdopen-2020-001472.
Kito K, Fukuda K, Kishimoto T, Yamashiro K, Yagami A. Treatment of vernal keratoconjunctivitis using Upadacitinib. JAMA Ophthalmol. 2024. https://doi.org/10.1001/jamaophthalmol.2024.1439.
Cohen F, Gabison EE, Stéphan S, Belkhir R, Nocturne G, Best AL, et al. Peripheral ulcerative keratitis in rheumatoid arthritis patients taking tocilizumab: paradoxical manifestation or insufficient efficacy? Rheumatology (Oxford). 2021;60(11):5413–8.
Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020;80:106210.
Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. Jak-stat signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77(5):521–46.
Clarke B, Yates M, Adas M, Bechman K, Galloway J. The safety of JAK-1 inhibitors. Rheumatology (Oxford). 2021;60(Suppl 2):ii24–30.
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–26.
Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169–81.
Wu Y, Wei M, Zhang J. A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib. Front Pharmacol. 2023;14:1200254.
Choy EH. Clinical significance of Janus kinase inhibitor selectivity. Rheumatology (Oxford). 2019;58(6):953–62.